FTC targets 'junk' patent listings on Ozempic and other drugs

The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and more.

Related Keywords

Texas ,United States ,Americans ,Lina Khan ,Covis Pharma ,Liz Essley Whyte ,Amphastar Pharmaceuticals ,Trademark Office ,Novartis Pharmaceuticals ,Teva Pharmaceutical Industries ,Novo Nordisk ,Drug Administration ,Astrazeneca ,Boehringer Ingelheim ,Orange Book ,Ozempic ,Ftc ,Us Ftc ,Federal Trade Commission ,Patent Listings ,Junk Patents ,Generic Drugs ,Diabetes Drugs ,Victoza ,Us Pharma Industry ,Us Pharma ,Ftc Chair Lina Khan ,Novartis Pharma ,Drug Patents ,Fda ,Usfda ,Drugmakers ,